News & Events
News & Events
Institut Pasteur Korea to Support Drug Discovery Screening for Promising Basic Research
2026-03-04
Institut Pasteur Korea to Support Drug Discovery Screening
for Promising Basic Research
– 2026 Open Call for Screening Collaboration Proposals (Application Deadline: March 25) –
– Free support for optimizing screening and conducting pilot compound screening–
for Promising Basic Research
– 2026 Open Call for Screening Collaboration Proposals (Application Deadline: March 25) –
– Free support for optimizing screening and conducting pilot compound screening–
(Mar. 4, 2026, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) announced on the 4th the launch of the “2026 Open Call for Screening Collaboration Proposals,” aimed at enhancing the value of outstanding basic research outcomes and facilitating their translation toward drug discovery and commercialization.
Through this program, IPK will provide selected projects with complimentary compound screening support using its AI-enhanced screening platform, which integrates high-throughput screening (HTS) and high-content screening (HCS) technologies. Leveraging automated experimental systems and advanced data analytics, the platform enables efficient, data-driven evaluation of compound activity in both target-based and cell-based assays.
In addition, IPK will actively promote collaborative research partnerships to ensure that validated hit compounds and other research outcomes generated through the program can be advanced into follow-up R&D, thereby accelerating their path toward commercialization.
Eligible applicants include researchers in science and engineering fields affiliated with Korean universities, national and public research institutes, government-funded research organizations, non-profit institutions, and hospitals who are capable of conducting collaborative research. Up to three projects will be selected. To provide broader opportunities, principal investigators selected in previous rounds of the same call will be excluded from the evaluation process.
Applicants must submit one completed application form in English via email. The submission deadline is March 25 at 12:00 PM (noon). Following document review and presentation evaluation, final selection results will be announced on April 29.
Further details regarding the call are available on the IPK website.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “We expect this program to enhance the value of basic research and accelerate drug discovery efforts by enabling the expansion of promising early-stage research outcomes into translational and applied research. We encourage active participation from researchers with innovative ideas and differentiated research capabilities.”